Bavarian Nordic to acquire the travel vaccine portfolio of Emergent BioSolutions for $380m.

Synopsis

Bavarian Nordic, a biotechnology company, agreed to acquire the travel vaccine portfolio of Emergent BioSolutions, a developer of vaccines, for $380m. “This acquisition adds not only to our commercial portfolio and reinforces our leading position in travel vaccines, but it also strengthens our pipeline," Paul Chaplin, Bavarian Nordic President and CEO.

Principals

target

Emergent Biosolutions (travel Vaccines Portfolios)

bidder

Bavarian Nordic

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (36)

Service Providers

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.